BPD
MCID: BRN056
MIFTS: 57

Bronchopulmonary Dysplasia (BPD)

Categories: Fetal diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Bronchopulmonary Dysplasia

MalaCards integrated aliases for Bronchopulmonary Dysplasia:

Name: Bronchopulmonary Dysplasia 20 58 54 37 62 70
Bpd 20 58

Characteristics:

Orphanet epidemiological data:

58
bronchopulmonary dysplasia
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Infancy,Neonatal; Age of death: normal life expectancy;

Classifications:

Orphanet: 58  
Rare respiratory diseases
Developmental anomalies during embryogenesis


External Ids:

MESH via Orphanet 45 D001997
ICD10 via Orphanet 33 P27.1
UMLS via Orphanet 71 C0006287
Orphanet 58 ORPHA70589
UMLS 70 C0006287

Summaries for Bronchopulmonary Dysplasia

PubMed Health : 62 About bronchopulmonary dysplasia: Bronchopulmonary (BRONG-ko-PUL-mo-NAR-e) dysplasia (dis-PLA-ze-ah), or BPD, is a serious lung condition that affects infants. BPD mostly affects premature infants who need oxygen therapy (oxygen given through nasal prongs, a mask, or a breathing tube). Most infants who develop BPD are born more than 10 weeks before their due dates, weigh less than 2 pounds (about 1,000 grams) at birth, and have breathing problems. Infections that occur before or shortly after birth also can contribute to BPD. Some infants who have BPD may need long-term breathing support from nasal continuous positive airway pressure (NCPAP) machines or ventilators.

MalaCards based summary : Bronchopulmonary Dysplasia, also known as bpd, is related to bronchial disease and newborn respiratory distress syndrome. An important gene associated with Bronchopulmonary Dysplasia is SFTPB (Surfactant Protein B), and among its related pathways/superpathways are Innate Immune System and NF-KappaB Family Pathway. The drugs Budesonide and Beractant have been mentioned in the context of this disorder. Affiliated tissues include Lung, and related phenotypes are emphysema and cough

GARD : 20 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 70589 Definition Bronchopulmonary dysplasia is a chronic respiratory disease that results from complications related to lung injury during the treatment of infant acute respiratory distress syndrome (see these terms) in low-birth-weight premature infants or from abnormal lung development in older infants. Clinical signs are tachypnea, tachycardia and signs of respiratory distress such as intercostal recession, grunting and nasal flaring.

Wikipedia : 73 Bronchopulmonary dysplasia (BPD; formerly chronic lung disease of infancy) is a chronic lung disease in... more...

Related Diseases for Bronchopulmonary Dysplasia

Diseases related to Bronchopulmonary Dysplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 296)
# Related Disease Score Top Affiliating Genes
1 bronchial disease 31.5 RNASE3 ELANE CXCL8
2 newborn respiratory distress syndrome 31.2 SFTPB SCGB1A1
3 chorioamnionitis 30.7 IL1RN FLT1 ELANE CXCL8
4 pulmonary edema 30.6 SCGB1A1 FGF7 CXCL8
5 gastroesophageal reflux 30.6 IL1RN ELANE CXCL8
6 neonatal respiratory failure 30.5 SFTPB SCGB1A1
7 pre-eclampsia 30.3 SOD1 SELL FLT1 CXCL8
8 interstitial lung disease 30.3 TIMP1 SFTPB CXCL8
9 pulmonary fibrosis 30.2 TIMP1 IL1RN FGF7 ELANE CXCL8
10 bronchitis 30.2 RNASE3 ELANE CXCL8
11 diaphragmatic hernia, congenital 30.2 SFTPB FGF7 FGF10
12 pustulosis of palm and sole 30.1 IL1RN CXCL8
13 bronchiolitis obliterans 30.1 TIMP1 SCGB1A1 CXCL8
14 bacterial infectious disease 30.0 SELL IL1RN ELANE CXCL8
15 pneumonia 30.0 SFTPB SELL SCGB1A1 ELANE CXCL8
16 allergic asthma 30.0 SCGB1A1 RNASE3 CXCL8
17 bacterial sepsis 29.9 IL1RN ELANE CXCL8
18 bronchopneumonia 29.9 ELANE CXCL8
19 extrinsic allergic alveolitis 29.9 SELL ELANE CXCL8
20 rhinitis 29.8 SCGB1A1 RNASE3 CXCL8
21 gastroenteritis 29.8 RNASE3 IL1RN CXCL8
22 pulmonary emphysema 29.8 TIMP1 FGF7 ELANE CXCL8
23 lung disease 29.7 TXN SOD1 SFTPB SCGB1A1 RNASE3 FGF7
24 adult respiratory distress syndrome 29.7 SOD1 SFTPB SCGB1A1 IL1RN FGF7 ELANE
25 proteasome-associated autoinflammatory syndrome 1 29.6 SELL RNASE3 IL1RN ELANE CXCL8
26 respiratory failure 29.4 TIMP1 SOD1 SFTPB SCGB1A1 RNASE3 RBP4
27 asthma 29.3 TIMP1 SELL SCGB1A1 RNASE3 IL1RN ELANE
28 pulmonary disease, chronic obstructive 29.1 TXN TIMP1 SFTPB SCGB1A1 RNASE3 ELANE
29 pulmonary fibrosis, idiopathic 28.6 TIMP1 SFTPB SCGB1A1 IL1RN FGF7 FGF10
30 heart disease 28.2 TIMP1 SOD1 SELL RBP4 IL1RN FLT1
31 borderline personality disorder 11.4
32 pulmonary hypertension, neonatal 11.0
33 pulmonary hypertension 11.0
34 patent ductus arteriosus 1 10.9
35 personality disorder 10.8
36 exudative vitreoretinopathy 1 10.7
37 respiratory distress syndrome in premature infants 10.7
38 cerebral palsy 10.7
39 enterocolitis 10.7
40 perinatal necrotizing enterocolitis 10.6
41 vascular disease 10.5
42 periventricular leukomalacia 10.5
43 pneumothorax 10.5
44 bronchiolitis 10.5
45 pulmonary interstitial emphysema 10.4
46 pulmonary hypertension, primary, 1 10.3
47 keratomalacia 10.3
48 yemenite deaf-blind hypopigmentation syndrome 10.3
49 rickets 10.3
50 avoidant personality disorder 10.3

Graphical network of the top 20 diseases related to Bronchopulmonary Dysplasia:



Diseases related to Bronchopulmonary Dysplasia

Symptoms & Phenotypes for Bronchopulmonary Dysplasia

Human phenotypes related to Bronchopulmonary Dysplasia:

58 31 (show all 22)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 emphysema 58 31 hallmark (90%) Very frequent (99-80%) HP:0002097
2 cough 58 31 hallmark (90%) Very frequent (99-80%) HP:0012735
3 premature birth 58 31 hallmark (90%) Very frequent (99-80%) HP:0001622
4 respiratory failure requiring assisted ventilation 58 31 hallmark (90%) Very frequent (99-80%) HP:0004887
5 respiratory distress 58 31 hallmark (90%) Very frequent (99-80%) HP:0002098
6 small for gestational age 58 31 hallmark (90%) Very frequent (99-80%) HP:0001518
7 chronic lung disease 58 31 hallmark (90%) Very frequent (99-80%) HP:0006528
8 hyperoxemia 58 31 hallmark (90%) Very frequent (99-80%) HP:0012419
9 sleep disturbance 58 31 frequent (33%) Frequent (79-30%) HP:0002360
10 diaphragmatic paralysis 58 31 frequent (33%) Frequent (79-30%) HP:0006597
11 central apnea 58 31 frequent (33%) Frequent (79-30%) HP:0002871
12 exercise intolerance 58 31 frequent (33%) Frequent (79-30%) HP:0003546
13 right ventricular hypertrophy 58 31 frequent (33%) Frequent (79-30%) HP:0001667
14 right ventricular failure 58 31 frequent (33%) Frequent (79-30%) HP:0001708
15 wheezing 58 31 frequent (33%) Frequent (79-30%) HP:0030828
16 atelectasis 58 31 occasional (7.5%) Occasional (29-5%) HP:0100750
17 tracheobronchomalacia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002786
18 pulmonary sequestration 58 31 occasional (7.5%) Occasional (29-5%) HP:0100632
19 dyspnea 58 Very frequent (99-80%)
20 abnormal lung morphology 58 Very frequent (99-80%)
21 abnormal respiratory system morphology 58 Frequent (79-30%)
22 functional respiratory abnormality 58 Frequent (79-30%)

MGI Mouse Phenotypes related to Bronchopulmonary Dysplasia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.91 ELANE FGF10 FGF7 FLT1 IL1RN SCGB1A1
2 homeostasis/metabolism MP:0005376 9.9 ELANE FGF10 FGF7 FLT1 IL1RN RBP4
3 immune system MP:0005387 9.61 ELANE FGF10 FGF7 FLT1 IL1RN SCGB1A1
4 reproductive system MP:0005389 9.23 FGF10 FGF7 FLT1 IL1RN RBP4 SELL

Drugs & Therapeutics for Bronchopulmonary Dysplasia

PubMed Health treatment related to Bronchopulmonary Dysplasia: 62

If your doctor thinks you're going to give birth too early, he or she may give you injections of a corticosteroid medicine. The medicine can speed up surfactant production in your baby. Surfactant is a liquid that coats the inside of the lungs . It helps keep the lungs open so your infant can breathe in air once he or she is born. Corticosteroids also can help your baby's lungs , brain , and kidneys develop more quickly while he or she is in the womb . Premature babies who have very low birth weights also might be given corticosteroids within the first few days of birth. Doctors sometimes prescribe inhaled nitric oxide shortly after birth for babies who have very low birth weights. This treatment can help improve the babies' lung function. These preventive measures may help reduce infants' risk of respiratory distress syndrome (RDS), which can lead to BPD.

Drugs for Bronchopulmonary Dysplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 229)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Budesonide Approved Phase 4 51333-22-3 63006 5281004
2
Beractant Approved Phase 4 108778-82-1
3
Procaterol Approved, Investigational Phase 4 72332-33-3 688561
4
Sodium citrate Approved, Investigational Phase 4 68-04-2
5
Caffeine Approved Phase 4 58-08-2 2519
6 Poractant alfa Approved Phase 4 129069-19-8
7
Zinc Approved, Investigational Phase 4 7440-66-6 32051
8
Zinc sulfate Approved, Investigational Phase 4 7733-02-0
9
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
10 Anti-Asthmatic Agents Phase 4
11 Hormone Antagonists Phase 4
12 Hormones Phase 4
13 Bronchodilator Agents Phase 4
14 glucocorticoids Phase 4
15 Albuterol Phase 4
16 Neurotransmitter Agents Phase 4
17 Phosphodiesterase Inhibitors Phase 4
18 Citrate Phase 4
19 Central Nervous System Stimulants Phase 4
20 Caffeine citrate Phase 4
21 Respiratory System Agents Phase 4
22 Pulmonary Surfactants Phase 4
23 Dermatologic Agents Phase 4
24
Furosemide Approved, Vet_approved Phase 2, Phase 3 54-31-9 3440
25
Spironolactone Approved Phase 2, Phase 3 1952-01-7, 52-01-7 5833
26
Chlorothiazide Approved, Vet_approved Phase 2, Phase 3 58-94-6 2720
27
Tocopherol Approved, Investigational Phase 3 1406-66-2
28
Calfactant Approved Phase 3 183325-78-2
29
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
30
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
31
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
32
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
33
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
34
Palivizumab Approved, Investigational Phase 2, Phase 3 188039-54-5
35
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
36
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
37
Ethanol Approved Phase 3 64-17-5 702
38
Benzyl alcohol Approved Phase 3 100-51-6 244
39
Clarithromycin Approved Phase 3 81103-11-9 84029
40
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
41
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
42
Nitric Oxide Approved Phase 2, Phase 3 10102-43-9 145068
43
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
44
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
45
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 68-26-8, 11103-57-4 445354
46
Cysteine Approved, Nutraceutical Phase 2, Phase 3 52-90-4 5862
47
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
48
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 1406-16-2
49
Vitamin D3 Approved, Nutraceutical Phase 2, Phase 3 67-97-0 6221 5280795
50
Ergocalciferol Approved, Nutraceutical Phase 2, Phase 3 50-14-6 5280793

Interventional clinical trials:

(show top 50) (show all 235)
# Name Status NCT ID Phase Drugs
1 Early Administration of Surfactant in Spontaneous Breathing (TAKE CARE) Versus InSurE (Intubation, Surfactant, Extubation) : A Pilot Study Unknown status NCT01329432 Phase 4
2 Prevention of Chronic Lung Disease (CLD) in Preterm Infants -A New Therapeutic Regimen Unknown status NCT00883532 Phase 4 budesonide;surfactant and air (placebo)
3 Routine Administration of Surfactant/Budesonide to Prevent BPD in VLBW With RDS-A Double Blind Study Unknown status NCT03275415 Phase 4 budesonide;Saline
4 The Role of Anti-Reflux Surgery for Gastroesophageal Reflux Disease in Premature Infants With Bronchopulmonary Dysplasia (BPD). Completed NCT00926276 Phase 4
5 Albuterol Dose-Response on Pulmonary Function Testing in Preterm Infants at Risk of Bronchopulmonary Dysplasia Completed NCT02447250 Phase 4 Varied albuterol dose response
6 Randomized Clinical Trial: Use of Azithromycin to Prevent Lung Damage in Preterm Newborns Under Mechanical Ventilation Completed NCT03485703 Phase 4 Azithromycin;Placebo
7 Efficacy of Adding Budesonide to Poractant Alfa to Prevent Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome. Recruiting NCT03521063 Phase 4 Budesonide;Poractant Alfa;Saline
8 A Randomized, Placebo-controlled Trial of Early Caffeine in Preterm Neonates Recruiting NCT03086473 Phase 4 Caffeine Citrate;Placebo (Normal Saline)
9 Exogenous Surfactant in Very Preterm Neonates Presenting With Severe Respiratory Distress in Prevention of Bronchopulmonary Dysplasia Active, not recruiting NCT01039285 Phase 4 Curosurf
10 Multicentre Randomised Controlled Trial of Minimally-invasive Surfactant Therapy in Preterm Infants 25-28 Weeks Gestation on Continuous Positive Airways Pressure Active, not recruiting NCT02140580 Phase 4
11 Oral Zinc Supplementation Improving Growth and Reducing Morbidity on Very Low Birth Weight Infant Not yet recruiting NCT04050488 Phase 4 Zinc Sulfate;Placebos
12 Rate of Bronchopulmonary Dysplasia in Preterms Neonates Less Than 29 Weeks' Gestational Age and / or With Birth Weight Less Than 1000 g: a Double Blind Randomized Controlled Multicenter Trial Comparing SMOFlipid and Medialipide Withdrawn NCT02853253 Phase 4
13 Prophylaxis of Bronchopulmonary Dysplasia With Clarithromycin Unknown status NCT01652118 Phase 3 clarithromycin treatment for prophylaxis of bronchopulmonary dysplasia;Saline
14 Trial of Late Surfactant for Prevention of Bronchopulmonary Dysplasia: A Study in Ventilated Preterm Infants Receiving Inhaled Nitric Oxide Unknown status NCT01022580 Phase 3 Infasurf surfactant (ONY, Inc.)
15 Determining the Effect of Spironolactone on Electrolyte Supplementation in Preterm Infants With Chronic Lung Disease Unknown status NCT01721655 Phase 2, Phase 3 Spironolactone;Placebo
16 Effect of Cysteine Supplementation on Glutathione Production in Critically Ill Neonates Unknown status NCT00254176 Phase 2, Phase 3
17 Effects of Fat-soluble Vitamins Supplementation in Early Life on Common Complications and Neural Development in Very Low Birth Weight Infants Unknown status NCT03876704 Phase 3 High dose of fat-Soluble Vitamin;Conventional dose of fat-Soluble Vitamin
18 Trial of Late Surfactant to Prevent BPD: A Pilot Study in Ventilated Preterm Neonates Receiving Inhaled Nitric Oxide Completed NCT00569530 Phase 3 Infasurf (ONY Inc.);Sham
19 Randomized Comparison of Two Models of Post-NICU Care for Preterm Infants With Neonatal Chronic Lung Disease Completed NCT00314431 Phase 3
20 Phase III Randomized, Double-Blind Study of Dexamethasone Vs Dexamethasone/Methylprednisolone Vs Placebo for Bronchopulmonary Dysplasia Completed NCT00004785 Phase 3 dexamethasone;methylprednisolone
21 Efficacy and Safety of NIPPV to Increase Survival Without Bronchopulmonary Dysplasia in Extremely Low Birth Weight Infants Completed NCT00433212 Phase 3
22 A Randomized Controlled Trial of Two Hemoglobin Thresholds for Transfusion in Newborns <1000g Birth Weight Completed NCT00182390 Phase 3
23 Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth Completed NCT00931632 Phase 3 Inhaled Nitric Oxide;Placebo
24 Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia Completed NCT01035190 Phase 3 Budesonide
25 Inhaled Nitric Oxide to Prevent and Treat Bronchopulmonary Dysplasia in Preterm Infants Completed NCT01503801 Phase 2, Phase 3 Nitric Oxide
26 Early Prevention of Broncho-pulmonary Dysplasia and Neonatal Mortality in Very Preterm Infants Using Low Dose of Hydrocortisone: a Randomized Controlled Trial Completed NCT00623740 Phase 3 hydrocortisone;placebo
27 Inhaled Beclomethasone to Prevent Chronic Lung Disease Completed NCT00000576 Phase 3 beclomethasone
28 High Frequency Ventilation in Premature Infants (HIFI) Completed NCT00000567 Phase 3
29 Inhaled NO in Prevention of Chronic Lung Disease Completed NCT00000548 Phase 3
30 Efficacy and Safety of Exosurf Neonatal and Survanta for the Treatment of Respiratory Distress Syndrome Completed NCT01203358 Phase 2, Phase 3 Exosurf;Survanta
31 Early Vitamin D Supplementation for Prevention of Respiratory Morbidity in Extremely Preterm Infants: A Randomized Clinical Trial Completed NCT01600430 Phase 2, Phase 3
32 A Prospective, Multicenter, Open-label, Non-comparative Study of Safety and Efficacy of Synagis in Children at High Risk of Severe Respiratory Syncytial Virus Infection in the Russian Federation Completed NCT01006629 Phase 2, Phase 3
33 A Randomized, Controlled Trial of Synchronized Nasal Intermittent Positive Pressure Ventilation Versus Nasal Continuous Positive Airway Pressure Using the Infant Flow Advance to Facilitate Successful Extubation in Premature Infants. Completed NCT00188968 Phase 3
34 Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants Completed NCT00233324 Phase 3 Surfactant;Supplemental oxygen with target saturation of 85 to 89%;Supplemental oxygen with target saturation of 91 to 95%
35 Inhaled NO for the Prevention of Chronic Lung Disease Completed NCT00006401 Phase 3 iNO
36 Randomized Clinical Trial of Dexamethasone Therapy in Very-Low-Birth-Weight Infants at Risk for Chronic Lung Disease (CLD) Completed NCT00011362 Phase 3 Dexamethasone Early;Dexamethasone Late
37 Effect of Autologous Cord Blood Mononuclear Cells for Prevention of Bronchopulmonary Dysplasia in Extremely Preterm Neonates: a Placebo-controlled Randomized Multicenter Trial Recruiting NCT04440670 Phase 3
38 Randomized Controlled Trial of Budesonide + Surfactant Versus Surfactant Alone in Extremely Preterm Infants ("The Budesonide in Babies (BiB) Trial") Recruiting NCT04545866 Phase 3 budesonide (Pulmicort nebulizing suspension).;surfactant (poractant alfa;Curosurf)
39 A Randomized Controlled Trial of Mid and Standard Frequency Ventilation in Infants With Respiratory Distress Syndrome Recruiting NCT03231735 Phase 2, Phase 3
40 Inhaled Nitric Oxide and Neuroprotection in Premature Infants Active, not recruiting NCT00515281 Phase 2, Phase 3 inhaled nitric oxide;oxygen
41 A Randomized Controlled Trial of the Effect Of Hydrocortisone on Survival Without Bronchopulmonary Dysplasia and on Neurodevelopmental Outcomes at 22 - 26 Months of Age in Intubated Infants < 30 Weeks Gestation Age Active, not recruiting NCT01353313 Phase 3 Hydrocortisone;Placebo
42 Maternal Omega-3 Supplementation to Reduce BronchopulmonarY Dysplasia in Very Preterm Infants (MOBYDIck Trial) Active, not recruiting NCT02371460 Phase 3
43 Transfusion of Prematures (TOP) Trial: Does a Liberal Red Blood Cell Transfusion Strategy Improve Neurologically-Intact Survival of Extremely-Low-Birth-Weight Infants as Compared to a Restrictive Strategy? Active, not recruiting NCT01702805 Phase 3
44 Treatment of Classic Mid-trimester Preterm Premature Rupture of Membranes (PPROM) With Oligo/Anhydramnion Between 22/0-26/0 Week of Gestation by Means of Continuous Amnioinfusion: a Multicenter Prospectiv Randomized Trial Not yet recruiting NCT04696003 Phase 3
45 The Use of Inhaled Nitric Oxide to Improve Respiratory Outcomes in Late Preterm Infants Terminated NCT01748045 Phase 2, Phase 3 inhaled nitric oxide;Placebo Comparator - nitrogen gas
46 Management of Hyponatremia in Preterm Infants on Diuretics Terminated NCT00156572 Phase 3
47 Randomized Trial of Minimal Ventilator Support and Early Corticosteroid Therapy to Increase Survival Without Chronic Lung Disease in Extremely-Low-Birth-Weight Infants Terminated NCT00005777 Phase 3 Dexamethasone;Placebo
48 Clinical Trial for the Prevention of Premature Birth and Neonatal Related Morbidity Terminated NCT00303082 Phase 3 Lactobacillus rhamnosus GR1 and Lactobacillus reuteri RC-14
49 A Randomised, Placebo Controlled Trial of Azithromycin for the Prevention of Chronic Lung Disease of Prematurity in Preterm Infants Withdrawn NCT02282176 Phase 3 Azithromycin;Placebo
50 Inhaled Extra-fine Hydrofluoalkane-beclomethasone (QVAR) in Premature Infants With Bronchopulmonary Dysplasia (BPD); Prospective, Double Blind, Randomized Placebo-control, Multi-center Study Unknown status NCT01373008 Phase 2 Inhaled extra-fine hydrofluoalkane-beclomethasone (QVAR)

Search NIH Clinical Center for Bronchopulmonary Dysplasia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Bronchopulmonary Dysplasia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Bronchopulmonary Dysplasia:
PNEUMOSTEM, cord blood-derived mesenchymal stem cells for bronchopulmonary dysplasia

Genetic Tests for Bronchopulmonary Dysplasia

Anatomical Context for Bronchopulmonary Dysplasia

MalaCards organs/tissues related to Bronchopulmonary Dysplasia:

40
Lung, Endothelial, Fetal Lung, Neutrophil, Bone Marrow, Heart, Smooth Muscle
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Bronchopulmonary Dysplasia:
# Tissue Anatomical CompartmentCell Relevance
1 Lung Pulmonary Capillary Plexus Affected by disease
2 Lung Alveoli Alveolar Epithelial Type 1 Cells Affected by disease, potential therapeutic candidate
3 Lung Alveoli Alveolar Epithelial Type 2 Cells Affected by disease, potential therapeutic candidate

Publications for Bronchopulmonary Dysplasia

Articles related to Bronchopulmonary Dysplasia:

(show top 50) (show all 7278)
# Title Authors PMID Year
1
Clara cell secretory protein (CC16) as a peripheral blood biomarker of lung injury in ventilated preterm neonates. 61 54
18521628 2008
2
Gastrin-releasing peptide, immune responses, and lung disease. 61 54
19076373 2008
3
Cord blood Clara cell protein CC16 predicts the development of bronchopulmonary dysplasia. 54 61
18521627 2008
4
FGF-10 is decreased in bronchopulmonary dysplasia and suppressed by Toll-like receptor activation. 61 54
17071719 2007
5
Selectin polymorphisms and perinatal morbidity in low-birthweight infants. 54 61
16982492 2006
6
Lower parathyroid hormone-related protein content of tracheal aspirates in very low birth weight infants who develop bronchopulmonary dysplasia. 54 61
16864707 2006
7
Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. 54 61
16856062 2006
8
The safety, pharmacokinetics, and anti-inflammatory effects of intratracheal recombinant human Clara cell protein in premature infants with respiratory distress syndrome. 54 61
15774846 2005
9
Erythrocyte Cu/Zn superoxide dismutase activity in preterm infants with and without bronchopulmonary dysplasia. 61 54
15767740 2005
10
Distribution of antioxidant enzymes in developing human lung, respiratory distress syndrome, and bronchopulmonary dysplasia. 61 54
15314090 2004
11
Neutrophil and monocyte adhesion molecules in bronchopulmonary dysplasia, and effects of corticosteroids. 54 61
14711863 2004
12
Interleukin-10 inhibits proinflammatory chemokine release by neutrophils of the newborn without suppression of nuclear factor-kappa B. 61 54
12788980 2003
13
Soluble E-selectin, soluble L-selectin and soluble ICAM-1 in bronchopulmonary dysplasia, and changes with dexamethasone. 61 54
12612222 2003
14
Roles for insulin-like growth factor I and transforming growth factor-beta in fibrotic lung disease. 61 54
12475802 2002
15
Secretoglobins SCGB3A1 and SCGB3A2 define secretory cell subsets in mouse and human airways. 54 61
12406855 2002
16
High concentrations of keratinocyte growth factor in airways of premature infants predicted absence of bronchopulmonary dysplasia. 61 54
12016100 2002
17
Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia. 54 61
11734454 2001
18
Monocyte chemoattractant protein-1 and interleukin-8 are increased in bronchopulmonary dysplasia: relation to isolation of Ureaplasma urealyticum. 61 54
11478413 2001
19
Superoxide dismutase for preventing chronic lung disease in mechanically ventilated preterm infants. 61 54
11279743 2001
20
Effects of early inhaled beclomethasone therapy on tracheal aspirate inflammatory mediators IL-8 and IL-1ra in ventilated preterm infants at risk for bronchopulmonary dysplasia. 61 54
11015126 2000
21
An alternatively spliced surfactant protein B mRNA in normal human lung: disease implication. 54 61
10493923 1999
22
Hyperoxia induces thioredoxin and thioredoxin reductase gene expression in lungs of premature baboons with respiratory distress and bronchopulmonary dysplasia. 61 54
10424622 1999
23
Effect of oxygen on lung superoxide dismutase activities in premature baboons with bronchopulmonary dysplasia. 61 54
9887057 1999
24
Elevated interleukin-8 concentrations in amniotic fluid of mothers whose neonates subsequently develop bronchopulmonary dysplasia. 54 61
9605441 1998
25
L-selectin expression on polymorphonuclear leukocytes and monocytes in premature infants: reduced expression after dexamethasone treatment for bronchopulmonary dysplasia. 61 54
9470000 1998
26
Elevation of interleukin-8 and interleukin-6 precedes the influx of neutrophils in tracheal aspirates from preterm infants who develop bronchopulmonary dysplasia. 54 61
9407566 1997
27
Cromolyn sodium prophylaxis inhibits pulmonary proinflammatory cytokines in infants at high risk for bronchopulmonary dysplasia. 61 54
9372670 1997
28
Airway lesions and superoxide dismutase (SOD) distribution in bronchopulmonary dysplasia (BPD). 54 61
9642974 1997
29
Amniotic fluid cytokines (interleukin-6, tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8) and the risk for the development of bronchopulmonary dysplasia. 54 61
9369827 1997
30
Eosinophil cationic protein in tracheal aspirates of preterm infants with bronchopulmonary dysplasia. 61 54
9202617 1997
31
Altered platelet-activating factor levels and acetylhydrolase activities are associated with increasing severity of bronchopulmonary dysplasia. 54 61
8853062 1996
32
Elevated cytokine levels in tracheobronchial aspirate fluids from ventilator treated neonates with bronchopulmonary dysplasia. 61 54
8775225 1996
33
Use of the intramuscular relative-dose-response test to predict bronchopulmonary dysplasia in premature infants. 61 54
8604659 1996
34
Secretory leukocyte protease inhibitor and lung inflammation in developing bronchopulmonary dysplasia. 61 54
7913723 1994
35
Proteinase-antiproteinase balance in tracheal aspirates from neonates. 61 54
7909297 1994
36
Pulmonary endocrine cells in infancy and childhood. 61 54
2014192 1991
37
Plasma retinol-binding protein response to vitamin A administration in infants susceptible to bronchopulmonary dysplasia. 54 61
2108233 1990
38
Can microsomal RNA be a biomarker in pulmonary hypertension secondary to bronchopulmonary dysplasia? 61
31248305 2021
39
Morbidity and cost burden of prenatal myelomeningocele repair. 61
31345076 2021
40
Evaluation of recombinant human SP-D in the rat premature lung model. 61
33444741 2021
41
High urinary concentrations of parabens and bisphenol A in very low birth weight infants. 61
33453489 2021
42
Sildenafil beyond erectile dysfunction and pulmonary arterial hypertension: Thinking about new indications. 61
33226665 2021
43
Risk factors for re-hospitalization following neonatal discharge of extremely preterm infants in Canada. 61
33747317 2021
44
Perinatal factors associated with bubbly/cystic appearance in bronchopulmonary dysplasia: a nationwide, population-based cohort study in Japan. 61
31170848 2021
45
Chorioamnionitis and neurodevelopmental outcome in very preterm infants from 2007 to 2017-a population-based study. 61
33306864 2021
46
Obstetric and pediatric growth charts for the detection of fetal growth restriction and neonatal adverse outcomes in preterm newborns before 34 weeks of gestation. 61
31146604 2021
47
Loop Diuretics in Severe Bronchopulmonary Dysplasia: Cumulative Use and Associations with Mortality and Age at Discharge. 61
33152371 2021
48
N-acetyl-lysyltyrosylcysteine amide, a novel systems pharmacology agent, reduces bronchopulmonary dysplasia in hyperoxic neonatal rat pups. 61
33607217 2021
49
Reference values for N-terminal Pro-brain natriuretic peptide in premature infants during their first weeks of life. 61
33141298 2021
50
Quantifying Medication Exposure in Very Low Birth Weight Neonates. 61
31683322 2021

Variations for Bronchopulmonary Dysplasia

Expression for Bronchopulmonary Dysplasia

Search GEO for disease gene expression data for Bronchopulmonary Dysplasia.

Pathways for Bronchopulmonary Dysplasia

Pathways related to Bronchopulmonary Dysplasia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.57 TXN TIMP1 SELL RNASE3 IL1RN FGF7
2
Show member pathways
12.29 TIMP1 FLT1 FGF7 FGF10
3
Show member pathways
12 TIMP1 FLT1 FGF7 FGF10
4
Show member pathways
11.23 TIMP1 FLT1 FGF7 FGF10 CXCL8
5 11.13 TIMP1 FGF7 CXCL8
6 10.82 TIMP1 IL1RN CXCL8
7 10.56 TIMP1 FLT1 FGF7 FGF10 CXCL8

GO Terms for Bronchopulmonary Dysplasia

Cellular components related to Bronchopulmonary Dysplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.8 TXN TIMP1 SOD1 SCGB1A1 RBP4 IL1RN
2 extracellular space GO:0005615 9.73 TIMP1 SOD1 SFTPB SCGB1A1 RNASE3 RBP4
3 extracellular region GO:0005576 9.44 TXN TIMP1 SOD1 SFTPB SCGB1A1 RNASE3
4 secretory granule GO:0030141 9.33 SOD1 SCGB1A1 ELANE

Biological processes related to Bronchopulmonary Dysplasia according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 response to lipopolysaccharide GO:0032496 9.72 SCGB1A1 FGF10 ELANE
2 animal organ morphogenesis GO:0009887 9.69 SFTPB FGF7 FGF10
3 lung development GO:0030324 9.58 RBP4 FGF7 FGF10
4 chemotaxis GO:0006935 9.56 RNASE3 FLT1 FGF10 CXCL8
5 blood vessel morphogenesis GO:0048514 9.54 FLT1 FGF10
6 hair follicle morphogenesis GO:0031069 9.52 FGF7 FGF10
7 response to organic substance GO:0010033 9.5 TIMP1 SOD1 SCGB1A1
8 embryonic digestive tract development GO:0048566 9.49 FGF10 CXCL8
9 induction of positive chemotaxis GO:0050930 9.48 FGF10 CXCL8
10 positive regulation of keratinocyte proliferation GO:0010838 9.46 FGF7 FGF10
11 positive regulation of keratinocyte migration GO:0051549 9.43 FGF7 FGF10
12 branching involved in salivary gland morphogenesis GO:0060445 9.37 FGF7 FGF10
13 secretion by lung epithelial cell involved in lung growth GO:0061033 9.16 FGF7 FGF10
14 regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signaling GO:0060665 8.96 FGF7 FGF10
15 female genitalia morphogenesis GO:0048807 8.62 RBP4 FGF10

Molecular functions related to Bronchopulmonary Dysplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.5 TIMP1 FGF7 FGF10
2 protease binding GO:0002020 9.33 TIMP1 SELL ELANE
3 fibroblast growth factor receptor binding GO:0005104 9.26 FGF7 FGF10
4 type 2 fibroblast growth factor receptor binding GO:0005111 8.96 FGF7 FGF10
5 heparin binding GO:0008201 8.92 SELL FGF7 FGF10 ELANE

Sources for Bronchopulmonary Dysplasia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....